Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VIE

Viela Bio (VIE) Stock Price, News & Analysis

Viela Bio logo

About Viela Bio Stock (NASDAQ:VIE)

Advanced Chart

Key Stats

Today's Range
$53.01
$53.01
50-Day Range
$52.92
$53.20
52-Week Range
$25.02
$65.00
Volume
N/A
Average Volume
1.07 million shs
Market Capitalization
$2.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Receive VIE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viela Bio and its competitors with MarketBeat's FREE daily newsletter.

VIE Stock News Headlines

RGNX-Aktie erreicht 52-Wochen-Tief bei 9,28 US-Dollar
Next “Midnight Tweet” From Could Trigger Massive Gains
When President Trump hits the send button... GET READY! His next “Midnight Tweet” could help Americans target 627% gains within Hours!
Regenxbio Names Mitchell Chan CFO
2024 Fire Awards: Meet this year's Ablaze honorees
See More Headlines

VIE Stock Analysis - Frequently Asked Questions

Viela Bio, Inc. (NASDAQ:VIE) posted its earnings results on Sunday, February, 28th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.10. The company earned $9.34 million during the quarter, compared to analysts' expectations of $5.10 million.

Viela Bio (VIE) raised $150 million in an initial public offering on Thursday, October 3rd 2019. The company issued 7,500,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and Cowen served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Viela Bio investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Toast (TOST), Ginkgo Bioworks (DNA), Globant (GLOB) and Saia (SAIA).

Company Calendar

Last Earnings
2/28/2021
Today
6/05/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VIE
CIK
N/A
Fax
N/A
Employees
166
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$86.43 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$50 million
Price / Cash Flow
N/A
Book Value
$7.14 per share
Price / Book
7.42

Miscellaneous

Free Float
N/A
Market Cap
$2.91 billion
Optionable
Not Optionable
Beta
0.43
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:VIE) was last updated on 6/6/2025 by MarketBeat.com Staff
From Our Partners